EMA Revoked: Dimethyl fumarate Accord (dimethyl fumarate) — Accord Healthcare S.L.U.

View source ↗

Summary

EMA revoked the marketing authorization for Dimethyl fumarate Accord for multiple sclerosis indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Dimethyl fumarate Accord (dimethyl fumarate)

Snippet

Status: Revoked. Therapeutic area: Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis. MAH: Accord Healthcare S.L.U.. Decision date: 13/12/2023